The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Agios Pharmaceuticals's share price is €32.80.
Agios Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.97. Hence, Agios Pharmaceuticals's PS Ratio for today is 33.74.
The historical rank and industry rank for Agios Pharmaceuticals's PS Ratio or its related term are showing as below:
FRA:8AP'
s PS Ratio Range Over the Past 10 Years
Min: 16.96 Med: 52.7 Max: 2008
Current: 33.82
During the past 13 years, Agios Pharmaceuticals's highest PS Ratio was 2008.00. The lowest was 16.96. And the median was 52.70.
FRA:8AP's PS Ratio is ranked worse than 73.95% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:8AP: 33.82
During the past 13 years, Agios Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 53.00% per year. The lowest was -21.90% per year. And the median was 8.10% per year.
Back to Basics: PS Ratio
Agios Pharmaceuticals (FRA:8AP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agios Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Agios Pharmaceuticals's Share Price of today is €32.80. Agios Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Agios Pharmaceuticals (FRA:8AP) has a PS Ratio of 33.74 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Agios Pharmaceuticals and its competitors. This is 36% below median its historical median of 52.70. Over the past decade, Agios Pharmaceuticals' PS Ratio has ranged from 16.96 to 2,008.00. According to the industry distribution chart, Agios Pharmaceuticals ranks #690 out of 933 companies in the Biotechnology industry, placing it in the top 74%.
Is Agios Pharmaceuticals' PS Ratio too high?
Agios Pharmaceuticals' current PS Ratio of 33.74 is 36% below median its 10-year median of 52.70. Over the past 10 years, this metric has ranged from a low of 16.96 to a high of 2,008.00. The Biotechnology industry median PS Ratio is 9.64. Agios Pharmaceuticals' value of 33.74 is 250% above this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #690 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' PS Ratio compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #690 out of 933 companies for PS Ratio. This places Agios Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.64. Agios Pharmaceuticals' value of 33.74 is 250% above this benchmark. Historically, Agios Pharmaceuticals' own PS Ratio has ranged from 16.96 to 2,008.00 over the past decade. While the company's 10-year median is 52.70 vs. the industry median of 9.64, Agios Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current PS Ratio of 33.74 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current PS Ratio is 33.74, which is 36% below median its own 10-year median of 52.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current PS Ratio of 33.74. The stock's GF Value™ is €72.27, compared to a current price of €32.80 — trading 54.6% below its estimated fair value. The current PS Ratio is 33.74, which is 36% below median its 10-year median of 52.70 and 250% above the Biotechnology industry median of 9.64. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current PS Ratio is 33.74 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.80 is trading 54.6% below its estimated GF Value™ of €72.27.
Key valuation signals for FRA:8AP:
PS Ratio: 33.74 (36% below median its 10-year median of 52.70)
GF Value™: €72.27 vs. price of €32.80 (54.6% below fair value)
Industry Position: 250% above the Biotechnology median (#690 of 933)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
